prindi

Lipoprotein(a) and Benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol

autor
Schwartz, Gregory G.
Szarek, Michael
Bittner, Vera A.
Diaz, Rafael
Goodman, Shaun G.
Viigimaa, Margus
kollektiivautor
ODYSSEY Outcomes Committees and Investigators
vastutusandmed
Gregory G. Schwartz, Michael Szarek, Vera A. Bittner, Rafael Diaz, Shaun G. Goodman, and on behalf of ODYSSEY Outcomes Committees and Investigators, [Margus Viigimaa et al.]
allikas
Journal of the American College of Cardiology
kirjastus/väljaandja
American College of Cardiology
ajakirja aastakäik number kuu
Vol. 78, 5
ilmumisaasta
2021
leheküljed
p. 421–433 : ill
leitav
https://www.jacc.org/doi/epdf/10.1016/j.jacc.2021.04.102
https://doi.org/10.1016/j.jacc.2021.04.102
märksõna
kolesterool
patsiendid
inhibiitorid
lipoproteiinid
lipoproteiinide ainevahetus
südame-veresoonkonna haigused
võtmesõna
acute coronary syndrome
lipoprotein(a)
low-density lipoprotein cholesterol
PCSK9 inhibitor
ISSN
0735-1097
TTÜ struktuuriüksus
tervisetehnoloogiate instituut
keel
inglise
Uurimisrühm
Hüpertensiooni ja ateroskleroosi diagnostika ning ravi tehnoloogiate uurimisrühm
Schwartz, G. G., Szarek, M., Bittner, V. A., Diaz, R., Goodman, S. G., ODYSSEY Outcomes Committees and Investigators, Viigimaa, M. et al. Lipoprotein(a) and Benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol // Journal of the American College of Cardiology (2021) Vol. 78, 5, p. 421–433 : ill. https://www.jacc.org/doi/epdf/10.1016/j.jacc.2021.04.102 https://doi.org/10.1016/j.jacc.2021.04.102